PROTECT H2H is the first randomized IDE trial of an embolic protection device in TAVR to meet all primary and secondary safety and efficacy endpoints, representing a significant clinical and ...
Randomized IDE study met all primary and secondary safety and efficacy endpoints and demonstrated superior debris capture and significantly higher technical success versus the leading embolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results